

REMARKS


Claim 16 is currently pending.

Claim 16 is currently amended. No new matter has been introduced as a result of the amendment.

Claim 16 has been rejected under 35 U.S.C. §112 (1st ¶). Applicants have amended Claim 16 so as to be restricted to glioblastoma. Further, the effectiveness of the recited cannabinol is believed supported by the effectiveness of Δ⁹ - tetrahydrocannabinol since all of the claimed compounds are very closely (structurally) related.

The rejection of Claim 16 under 35 U.S.C. §112 (2nd ¶) is believed to be moot in view of the amendments made herein to Claim 16.

In view of the foregoing, Applicants respectfully request reconsideration and allowance of the sole pending Claim 16.

Respectfully submitted,


Bradley B. Geist
Patent Office Reg. No. 27,551

Attorneys for Applicants
(212) 408-2562